Researchers have been trying to develop antiretroviral medicines that can last for weeks, months or even years per dose. Two such long-acting formulations have been approved in South Africa, but several more are on the horizon. Elri Voigt explores the science behind what makes a formulation long-acting and takes a look at some particularly exciting prospects.
Study findings presented this week at a major HIV conference show that taking a statin every day substantially reduces the chances of suffering a major adverse cardiovascular event in people living with HIV who have a low-to-moderate risk of cardiovascular disease. The findings were also published in the New England Journal of Medicine. Elri Voigt unpacks the study findings and asks what it might mean for people in South Africa.
HIV in South Africa is not the crisis it was 20 years ago, and the country faces a growing burden of non-communicable diseases, but specific investments in HIV nevertheless continue to offer excellent value for money for governments and donors alike. As people gather for the 2023 International AIDS Society Conference in Brisbane, Australia, Marcus Low argues that while funding for HIV interventions remains absolutely essential, it is also critical for the future of the HIV response and people living with HIV that HIV should now be better integrated with other healthcare services, especially those for diabetes and hypertension.